skinny.

Latest / GK Daily Podcast

GK Daily Special Edition: The Antibiotic Paradox — Why Saving Lives Doesn't Pay the Bills

In the summer of 2018, a small California biotech called Achaogen did something almost no company manages to do. It got a brand-new antibiotic approved by the Food and Drug Administration, a drug called plazomicin built to fight infections that had stopped responding to everything else. Eight months later, the company filed for bankruptcy. Total sales for that first year on the market: eight hundred thousand dollars. Not eight hundred thousand patients. Eight hundred thousand dollars, for a drug the government had fast-tracked as a breakthrough therapy, after fifteen years of research. For...

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.